Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Apr;8(7):518.
doi: 10.21037/atm.2020.03.76.

Potential of combination therapy in EGFR mutated lung cancer

Makoto Maemondo  1
Affiliations
Comment

Potential of combination therapy in EGFR mutated lung cancer

Makoto Maemondo. Ann Transl Med. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.76). The author received lecture fees from Chugai Pharmaceutical., AstraZeneca, and Boehringer and has been supported through clinical studies by Chugai Pharmaceutical.

Comment on

References

    1. Adderley H, Ackermann CJ, Califano R. Erlotinib plus bevacizumab, ready for first-line? Ann Transl Med 2019;7:S346. 10.21037/atm.2019.09.116 - DOI - PMC - PubMed
    1. Horinouchi H. To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR-mutation-positive non-small-cell lung cancer. Ann Transl Med 2020. doi: 10.21037/atm.2020.01.66 - DOI - PMC - PubMed
    1. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo controlled, phase 3 trial. Lancet Oncol 2019;20:1655-69. 10.1016/S1470-2045(19)30634-5 - DOI - PubMed
    1. Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 2019;20:625-35. 10.1016/S1470-2045(19)30035-X - DOI - PubMed
    1. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an openlabel, randomised, multicentre, phase 2 study. Lancet Oncol 2014;15:1236-44. 10.1016/S1470-2045(14)70381-X - DOI - PubMed